Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|August 2, 2022
- Pharmaceutical Technology, August 2022
- Volume 46
- Issue 8
Accurate Level Switches
Author(s)Pharmaceutical Technology Editors
The Dynatrol G Series Level Switches are designed to accurately measure light or heavier bulk solids for problem applications.
The Dynatrol G Series Level Switches are intended for special problem applications involving very light or fluffy products or for heavier bulks solids that pack or bridge easily. Designed for accuracy on high, intermediate, or low-point level detection, the switches are built to work in dusty environments, while specialized units can be used in temperatures exceeding 300°F.
The Type GJ switch is designed for pharmaceutical powders, powder materials for coating beads and tablets, fillers, and other substances that vary widely in bulk density or particle size. The Type GS and GSS switches are also intended for fine powders while working with beads as light as polystyrene, for example, as well.
Articles in this issue
about 4 years ago
What Goes Wrong When API Quality is Compromised?about 4 years ago
Mitigating the Risk from Excipient Variabilityabout 4 years ago
Adapting to Solubility/Bioavailability Challengesabout 4 years ago
Progress in the Development of CAR NK-Cell Therapiesabout 4 years ago
Vaccine Administration: The Growing Role of Prefilled Syringesabout 4 years ago
Inspecting Finished Products with Precisionabout 4 years ago
An Integrated Approach to the Data Lifecycle in BioPharmaabout 4 years ago
Detecting Apparent Total Nitrosamine Content in Pharmaceutical DrugsRelated to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Complying with International Pharmacopoeias
3
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
4
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
5